

Review on Principles and Etiopathogenesis of Ameloblastoma

Mohandas R¹, Mohapatra S^{2*}

¹Assistant Professor, Department of Oral and Maxillofacial Pathology and Oral Microbiology, Dr. D.Y. Patil Dental College and Hospital, Dr. D.Y. Patil Vidyapeeth, Pimpri, Pune – 18.

^{2*}Assistant Professor, Department of Public Health Dentistry, Dr. D.Y. Patil Dental College and Hospital, Dr. D.Y. Patil Vidyapeeth, Pimpri, Pune – 18

Abstract

Ameloblastoma, a rare odontogenic tumor that has fascinated clinicians and researchers for decades. This review delves into the tumor's origin, deeply investigating the etiopathogenesis rooted in the odontogenic epithelium associated with enamel formation. It elucidates key cellular and molecular mechanisms driving its development, shedding light on the intricate factors governing initiation and progression. Furthermore, the review focuses on the management of ameloblastoma, with an emphasis on surgical interventions. This review also addresses the vexing issue of tumor recurrence and the potential complications that can arise during and after treatment. By examining these issues in detail, it offers essential insights into effective strategies for managing these aspects of ameloblastoma, ensuring that clinicians and researchers are well-equipped to navigate the complexities of this unique odontogenic tumor. In summary, this review offers a holistic and in-depth exploration of ameloblastoma, from its origins to its management and the challenges it presents to the medical community.

Keywords: ameloblastoma, benign, etiopathogenesis, tumour, management

Address for correspondence: Mohapatra S, Assistant Professor, Department of Public Health Dentistry, Dr. D.Y. Patil Dental College and Hospital, Dr. D.Y. Patil Vidyapeeth, Pimpri, Pune – 18.

email: subhashreesdc@gmail.com

How to cite this article: Mohandas R, Mohapatra S, Review on Principles and Etiopathogenesis of Ameloblastoma. *Int J Clinicopathol Correl.* 2023;7:2:29-33.

Submitted: 16-Sep-2023 **Revised:** 16-Oct- 2023 **Accepted:** 17-Oct-2023 **Published:** 31-Oct-2023

Introduction

Ameloblastoma, an exceedingly rare and captivating odontogenic tumor, stands as a unique and formidable challenge that has captured the intrigue of researchers and clinicians alike. This benign yet profoundly locally invasive tumor finds its origins within the odontogenic epithelium, a tissue with a fundamental role in enamel formation during the intricate process of tooth development. Through the years, the perplexing clinical behavior of ameloblastoma, characterized by its propensity for unpredictability and high recurrence rates, has left medical professionals astounded. Consequently, this enigmatic tumor

has become the subject of relentless scrutiny and rigorous investigation (1). Arising from remnants of the odontogenic epithelium, ameloblastoma displays a deliberate and infiltrative growth pattern, an attribute that distinguishes it from other benign neoplasms. Despite its benign nature, this locally aggressive tendency sets ameloblastoma apart

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

DOI: <https://doi.org/10.56501/intjclinicopatholcorrel.v7i2.916>
Copy right © 2023 Mohandas R, Mohapatra S

as a unique entity in the realm of tumors. Its preference for manifestation primarily within the jawbones, particularly the mandible, further contributes to its mystique, although it can also present itself in the maxilla (2). Intriguingly, this odontogenic tumor, with its ability to mimic the very tissue responsible for enamel formation, serves as a compelling enigma in the field of oral and maxillofacial pathology. Its rarity, combined with its clinical behavior, incites both fascination and the pressing need for a deeper understanding. As researchers and clinicians grapple with the complexities of ameloblastoma, they endeavor to unravel its mysteries, improve diagnostic accuracy, and develop more effective treatment strategies to combat its locally invasive tendencies and reduce the risk of recurrence. Ameloblastoma typically presents as a slow-growing, painless swelling in the jaw area. Its clinical manifestations may vary widely, making diagnosis challenging. Common symptoms include facial deformity, loose teeth, and in some cases, pain or discomfort. Radiographic imaging, such as panoramic X-rays or CT scans, plays a vital role in the diagnostic process(3). Histologically, ameloblastomas are classified into several subtypes, including: Conventional/Classic Ameloblastoma: The most common subtype, displaying a follicular or plexiform pattern. Unicystic Ameloblastoma: Occurs as a unilocular cystic lesion with minimal or no mural proliferation. Multicystic Ameloblastoma: Characterized by the presence of multiple small cystic spaces within the tumor. Peripheral Ameloblastoma: Found at the soft tissue-oral mucosal junction, with a less aggressive behavior compared to intraosseous ameloblastomas (4).

Understanding the underlying mechanisms and clinical manifestations of ameloblastoma is crucial for improved diagnosis, treatment, and long-term management. This article aims to provide a comprehensive overview of ameloblastoma, examining its clinical features, pathology, and therapeutic strategies, all rooted in scientific evidence and the latest research findings. The fascination with ameloblastoma lies not only in its rarity but also in its

challenging nature. It forces us to confront a tumor that, despite its benign classification, behaves with an aggressiveness that demands our attention. By unraveling the intricacies of ameloblastoma, we hope to contribute to a deeper understanding of this enigmatic tumor and enhance the quality of care provided to patients affected by it.

Etiopathogenesis

The exact etiology of ameloblastoma remains elusive, but several theories have been proposed: Ameloblastomas are thought to arise from remnants of the odontogenic epithelium, which includes the dental lamina, enamel organ, and the epithelial rests of Malassez. The development of ameloblastomas may result from these remnants undergoing neoplastic transformation. Genetic predisposition may play a role in the development of ameloblastomas (5). Certain mutations in the CTNNB1 (beta-catenin) gene have been associated with ameloblastoma, contributing to the activation of the Wnt signaling pathway and promoting tumor growth. While there is no direct evidence linking environmental factors to ameloblastoma, factors such as ionizing radiation exposure and chemical agents have been explored as potential contributors. Ameloblastomas often exhibit aneuploidy and high proliferative potential, suggesting that genetic and chromosomal abnormalities may contribute to their development and aggressive behavior (6).

Underlying molecular mechanism of Ameloblastoma

Sonic Hedgehog (SHH) Pathway: A key player in the pathogenesis of ameloblastoma is the Sonic Hedgehog (SHH) pathway. SHH, a mammalian homolog of the *Drosophila* segment polarity gene Hedgehog, encodes a secreted protein that activates a membrane receptor complex comprising patched 1 (PCTH 1) and smoothed (SMO). In the absence of SHH, PCTH inhibits SMO. When PCTH binds to SHH, SMO is released, leading to the activation of glioma-associated (GLI 1) family transcription factor genes (7). This activation

mediates SHH signaling from the cytoplasm to the nucleus. Studies have reported high expression levels of SHH, SMO, and GLI 1 in ameloblastoma. Moreover, the benign and metastasizing types of ameloblastoma have shown stronger PCTH 1 expression in neoplastic cells compared to stromal cells. This suggests that SHH signaling molecules may play a role in epithelial-mesenchymal interaction and cell proliferation within ameloblastoma (8)

WNT Pathway: The WNT genes encode glycoproteins and are divided into canonical β -catenin and noncanonical β -catenin-independent pathways. WNT 5a signaling plays a crucial role in modulating tumorigenesis and behavior of enamel epithelial cells in ameloblastoma. Overexpression of WNT 5a enhances enamel epithelial cell migration, while suppression impairs migration and actin reorganization. The canonical WNT pathway stabilizes β -catenin and translocates it into the nucleus, influencing gene transcription, a mechanism evident in ameloblastomas (9).

Bone Morphogenetic Protein (BMP) Pathway: BMP, a mesenchymal cell differentiation factor, is essential for cell proliferation, differentiation, chemotaxis, extracellular matrix (ECM) production, and apoptosis during development. Studies have examined BMP expression in various odontogenic tissues and found BMPs and BMP receptors in odontogenic epithelial cells. Acanthomatous ameloblastomas exhibit increased BMP-7 reactivity in keratinizing cells. In contrast, ameloblastic carcinomas display low reactivity for BMPs, BMP receptors, and core-binding factor alpha 1 (CBFA 1) (10).

SMAD Proteins: SMAD proteins regulate the transforming growth factor β (TGF β) and BMP pathways. SMAD 2/3 primarily mediates the TGF β pathway and has tumor-suppressing functions. In contrast, SMAD 3 plays a role in TGF β -induced inflammation. The TGF β /SMAD signaling pathway plays a crucial role in the invasiveness of ameloblastoma, particularly in later stages, where it promotes

tumor invasion. The exact mechanisms remain unclear, necessitating further research (11).

Expression of Enamel Matrix Proteins: Ameloblastin, anamelin, and sheathlin proteins are not expressed in ameloblastoma, indicating that functional maturation of ameloblasts does not occur in tumor cells. However, amelogenin is transcribed only by differentiated ameloblasts and is expressed by amelostatic epithelial cells (12).

Molecular Markers for Cell Adhesion and Migration: Syndecan-1, a transmembrane heparan sulfate proteoglycan, is associated with cytoskeletal organization, growth factor signaling, cell-to-cell signaling, and ECM attachment. Its decreased expression in ameloblastomas is indicative of aggressive behavior. Cadherins, keratin 7 (KRT 7), and Notch are cell adhesion molecules that communicate with intercellular controls. Loss of E-cadherin and integrins, such as $\alpha 5 \beta 1$, contribute to tumor progression and invasion in ameloblastoma (13).

Claudins: Claudins are proteins found in tight junctions, participating in embryogenesis and organogenesis. Increased expression of claudin 1, 4, and 7 in ameloblastoma indicates efforts to maintain cell-to-cell adhesion. Decreased claudin 7 expression is linked to invasive behavior in carcinomas (14).

Other Molecular Markers: Podoplanin, metallothionein (MT), p16, Ki-67, cyclin D1, telomerase, proliferating nuclear cell antigen (PCNA), telomerase reverse transcriptase (TERT), and various cytokines and growth factors have been investigated as potential markers of cell proliferation, apoptosis, tumor growth, angiogenesis, and bone remodeling in ameloblastoma (15). The presence of myofibroblasts is an important prognostic marker for the aggressiveness of ameloblastoma. The expression of CD 10, a cell surface zinc-dependent metalloprotease glycoprotein, is associated with tumor dysplasia and has been linked to the likelihood of recurrence in ameloblastoma. Complex

molecular pathways and markers involved in the etiopathogenesis of ameloblastoma provides valuable insights into its development and behavior (16). Further research into these pathways and markers may lead to improved diagnostic and treatment strategies for this enigmatic oral and maxillofacial tumor.

Diagnosis and Management

Diagnosis of ameloblastoma involves clinical examination, imaging studies (like panoramic radiographs and CT scans), and histopathological evaluation of a biopsy specimen. Treatment typically involves surgical resection, which can be challenging due to the tumor's infiltrative nature. Complete removal of the lesion is crucial to prevent recurrence. Depending on the tumor type and size, treatment options may include conservative enucleation, en bloc resection, or segmental resection. Regular postoperative follow-ups are essential to monitor for recurrence (17).

Conclusion

Ameloblastoma is a fascinating yet complex oral and maxillofacial pathology that continues to challenge researchers and clinicians alike. While the exact etiology remains uncertain, ongoing research is shedding light on the genetic and molecular underpinnings of this enigmatic tumor. With improved diagnostic techniques and treatment strategies, there is hope for better outcomes for patients with ameloblastoma in the future. Nevertheless, the mysterious and unpredictable nature of this neoplasm continues to captivate the dental and medical community, inspiring further research to uncover its secrets.

Conflict of Interest: NIL

Source of Funding: NIL

Acknowledgment: The authors were grateful to thank the study participants for their participation and kind cooperation.

Reference

1. Anyanechi CE, Shetty SS. Ameloblastoma of the jaws in adult: A retrospective review of local recurrent lesions based on the resection margin in the adjacent apparent healthy tissues. *Heliyon*. 2023 May;9(5):e16243.
2. Kono T, Abe A, Noguchi K, Uchida K, Shinoda M, Kawano K. Extralingival peripheral ameloblastoma arising in the infratemporal fossa: A case report with an assessment of proliferative activity. *Oral Sci Int*. 2023 Jan;20(1):36–41.
3. Black AI, Machete ML, Motloba PD. A 30-year review of ameloblastoma: A tertiary hospital-based study. *South African Dental Journal*. 2023 May 1;78(4):184-9.
4. Bwambale P, Yahaya JJ, Owor G, Wabinga H. Histopathological patterns and biological characteristics of ameloblastoma: A retrospective cross-sectional study. *J Taibah Univ Med Sci*. 2022 Feb;17(1):96–104.
5. Nagi R, Sahu S, Rakesh N. Molecular and genetic aspects in the etiopathogenesis of ameloblastoma: An update. *J Oral Maxillofac Pathol*. 2016 Sep-Dec;20(3):497–504.
6. Effiom OA, Ogundana OM, Akinshipo AO, Akintoye SO. Ameloblastoma: current etiopathological concepts and management. *Oral Dis*. 2018 Apr;24(3):307–16.
7. Mishra P, Panda A, Bandyopadhyay A, Kumar H, Mohiddin G. Sonic Hedgehog Signalling Pathway and Ameloblastoma - A Review. *J Clin Diagn Res*. 2015 Nov;9(11):ZE10–3.
8. Carballo GB, Honorato JR, de Lopes GPF, Spohr TCL de SE. A highlight on Sonic hedgehog pathway. *Cell Commun Signal*. 2018 Mar 20;16(1):11.

9. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. *Dev Cell*. 2009 Jul;17(1):9–26.
10. Nascimento MAB, Nonaka CFW, Barboza CAG, Freitas R de A, Pereira Pinto L, Souza LB de. Immunoexpression of BMP-2 and BMP-4 and their receptors, BMPR-IA and BMPR-II, in ameloblastomas and adenomatoid odontogenic tumors. *Arch Oral Biol*. 2017 Jan;73:223–9.
11. Karathanasi V, Tosios KI, Nikitakis NG, Piperi E, Koutlas I, Trimis G, et al. TGF- β 1, Smad-2/-3, Smad-1/-5/-8, and Smad-4 signaling factors are expressed in ameloblastomas, adenomatoid odontogenic tumors, and calcifying cystic odontogenic tumors: an immunohistochemical study. *J Oral Pathol Med*. 2013 May;42(5):415–23.
12. Anigol P, Kamath VV, Satelur K, Anand N, Yerlagudda K. Amelogenin in odontogenic cysts and tumors: An immunohistochemical study. *Natl J Maxillofac Surg*. 2014 Jul-Dec;5(2):172–9.
13. Carreón-Burciaga RG, González-González R, Molina-Frechero N, López-Verdín S, Pereira-Prado V, Bologna-Molina R. Differences in E-Cadherin and Syndecan-1 Expression in Different Types of Ameloblastomas. *Anal Cell Pathol*. 2018 Apr 23;2018:9392632.
14. Phattarataratip E, Sappayatosok K. The Significance of Relative Claudin Expression in Odontogenic Tumors. *Head Neck Pathol*. 2020 Jun;14(2):480–8.
15. Chopra S, Bansal P, Bansal P. *Journal of Advanced Medical and Dental Sciences Research* | Vol. 8 | Issue 1|. *J Adv Med Dent Scie Res*. 2020;8(1):184-6.
16. Zhong Y, Guo W, Wang L, Chen X. Molecular markers of tumor invasiveness in ameloblastoma: An update. *Ann Maxillofac Surg*. 2011 Jul;1(2):145–9.
17. ELmrini S, Raiteb M, Bahaa Razem, Hassani FZA, Slimani F. Ameloblastoma giant: Diagnosis, treatment and reconstruction: A case report. *Ann Med Surg (Lond)*. 2021 Aug;68:102589.